Anacor, Regeneron Up On Promising Rash Treatments

By | July 13, 2015

Scalper1 News

Biotechs Anacor Pharmaceuticals (ANAC) and Regeneron Pharmaceuticals (REGN) were both trading up Monday on the potential of their drug candidates for atopic dermatitis (AD). Anacor stock soared 55% to a new high above 131 on the strength of late-stage trial results for its ointment Crisaborole. The company said half the patients with mild to moderate AD — a recurring skin inflammation of unknown origin — were clear or almost clear of the rash Scalper1 News

Scalper1 News